News

Hims Reaffirms 2025 Sales Guidance After Posting Quarterly Beat
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Fierce Healthcare13h
Hims & Hers' Q1 revenue doubles to $586M, boosted by growth in weight loss business
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
24/7 Wall St. on MSN12h
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Imitation weight-loss drugs boosted Hims & Hers. Executives cashed in.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims outlines 2030 targets with $6.5B revenue and $1.3B EBITDA projections
Explore Hims & Hers' impressive Q1 2025 growth with 111% revenue increase, strategic partnerships, and innovative healthcare solutions.
Buffett succession, Palantir earnings preview, Hims COO pick
At Berkshire Hathaway's (BRK-B, BRK-A) annual shareholders meeting over the weekend, chairman and CEO Warren Buffett, 94, ...
Up 30% In A Week, HIMS Stock Is Just Getting Warmed Up
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Modern Healthcare20h
Hims & Hers names Amazon exec as chief of operations
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Hims & Hers Stock Stumbles After Earnings. The Long-Term Sales Outlook Looks Low.
Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...